In our tumor graft models, this chemerin bioactivity is essentially targeted toward endothelial cells, resulting in an impairment of the tumor vascularization, leading to hypoxia and cell death by apoptosis and necrosis. The gene discussed is RARRES2; the disease is neoplasm.